{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:50Z","timestamp":1788922130982,"version":"build-2803163510"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Collegium Pharmaceuticals Inc"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Abuse deterrent formulation (ADF) products are designed to prevent people from tampering with medication, especially with the intention to misuse or abuse the product. While clinical results support the efficacy of ADF products in controlled settings, little is known about how people use and abuse them in the real world. The objective of this research was to describe tampering behavior and perceived risk among U.S. adults who report non-medical use (NMU) of XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER, a novel ADF extended-release opioid, and comparable products. A cross-sectional survey was conducted in 2021 and 2022 among adults who reported NMU of oxycodone or hydrocodone products in the past year. To compare use patterns and tampering behavior to XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER, three similar opioid products were also assessed. Participants who reported NMU of an eligible drug were asked why they used it, how they tempered with it, and what other drug-related behaviors they engaged in. A total of 628 participants were recruited. A total of 56 (8.92%) reported NMU of XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER in the past year, 256 (40.8%) reported NMU of other ADF ER oxycodone\/hydrocodone, 459 (73.1%) reported NMU of non-ADF ER oxycodone\/hydrocodone, and 225 (35.8%) reported NMU of IR oxycodone. Non-ADF ER oxycodone\/hydrocodone was the most used. Those who reported NMU of XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER had more severe drug use profiles, including higher scores on the 10-item Drug Abuse Screening Test (DAST-10) and higher prevalence of concomitant and illicit drug use. Overall, 3.7% tampered with XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER, 12.9% tampered with other ADF ER oxycodone\/hydrocodone, 16.0% tampered with non-ADF ER oxycodone\/hydrocodone, and 10.7% tampered with IR oxycodone. U.S. adults who reported tampering with XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER or a comparable product frequently did so for therapeutic reasons, most commonly \u201cto swallow the pill more easily\u201d and \u201cto improve the pain relief from the pill.\u201d They also viewed tampering with products they used as less risky than tampering with products they did not use. Tampering with XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER was uncommon compared to other drugs but more common as a proportion among those who used XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER. This is, potentially because those using XTAMPZA<jats:sup>\u00ae<\/jats:sup> ER had other markers of severe, problematic drug use.<\/jats:p>","DOI":"10.1371\/journal.pone.0332574","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:31:12Z","timestamp":1759944672000},"page":"e0332574","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Motivations, perceived risk, and tampering of XTAMPZA ER and abuse-deterrent opioid drugs"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-794X","authenticated-orcid":true,"given":"Hannah L.","family":"Burkett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"pone.0332574.ref001","author":"National Survey on Drug Use and Health 2020","year":"2022"},{"issue":"4","key":"pone.0332574.ref002","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamainternmed.2018.6989","article-title":"County-Level Opioid Prescribing in the United States, 2015 and 2017","volume":"179","author":"Jr Guy GP","year":"2019","journal-title":"JAMA Intern Med"},{"key":"pone.0332574.ref003","article-title":"Update on abuse-resistant and abuse-deterrent approaches to opioid formulations","author":"L Webster","year":"2009","journal-title":"Pain Med"},{"issue":"4","key":"pone.0332574.ref004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/papr.12760","article-title":"Mitigation of IV abuse through the use of abuse-deterrent opioid formulations: an overview of current technologies","volume":"19","author":"RL Rauck","year":"2019","journal-title":"Pain Pract"},{"key":"pone.0332574.ref005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","article-title":"Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration","volume":"175","author":"JL Green","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"pone.0332574.ref006","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.mayocp.2012.02.022","article-title":"Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering","volume":"87","author":"SP Stanos","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"pone.0332574.ref007","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"KE Vowles","year":"2015","journal-title":"Pain"},{"issue":"12","key":"pone.0332574.ref008","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40261-017-0599-8","article-title":"Author correction to: In vitro drug release after crushing: evaluation of Xtampza","volume":"37","author":"SP Mayock","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"12","key":"pone.0332574.ref009","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40261-017-0561-9","article-title":"In vitro drug release after crushing: evaluation of xtampza","volume":"37","author":"SP Mayock","year":"2017","journal-title":"Clin Drug Investig"},{"key":"pone.0332574.ref010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2016.09.018","article-title":"Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone","volume":"168","author":"SG Severtson","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"pone.0332574.ref011","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5055\/jom.2014.0211","article-title":"Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx\u00ae: an extended-release, abuse-deterrent formulation","volume":"10","author":"EA Kopecky","year":"2014","journal-title":"J Opioid Manag"},{"issue":"4","key":"pone.0332574.ref012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5055\/jom.2014.0211","article-title":"Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx\u00ae: an extended-release, abuse-deterrent formulation","volume":"10","author":"EA Kopecky","year":"2014","journal-title":"J Opioid Manag"},{"issue":"8","key":"pone.0332574.ref013","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/pm\/pnx151","article-title":"Relative abuse of crush-resistant prescription opioid tablets via alternative oral modes of administration","volume":"19","author":"SF Butler","year":"2018","journal-title":"Pain Med"},{"key":"pone.0332574.ref014","year":"2017"},{"issue":"8","key":"pone.0332574.ref015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/pds.5260","article-title":"Drug product dispensing and estimates of use in a general population survey as a signal detection problem","volume":"30","author":"JC Black","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"pone.0332574.ref016","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<981::AID-SIM510>3.0.CO;2-N","article-title":"Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence","volume":"16","author":"H Brenner","year":"1997","journal-title":"Stat Med"},{"issue":"10","key":"pone.0332574.ref017","doi-asserted-by":"crossref","DOI":"10.2196\/15830","article-title":"An Online Survey for Pharmacoepidemiological Investigation (Survey of Non-Medical Use of Prescription Drugs Program): Validation Study","volume":"21","author":"JC Black","year":"2019","journal-title":"J Med Internet Res"},{"issue":"2","key":"pone.0332574.ref018","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jsat.2006.08.002","article-title":"A comprehensive review of the psychometric properties of the Drug Abuse Screening Test","volume":"32","author":"E Yudko","year":"2007","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"pone.0332574.ref019","first-page":"51","article-title":"What can real-world evidence contribute to regulatory science in pre- and post- marketing setting?","volume":"2","author":"J Sultana","year":"2020","journal-title":"Pharmadvances"},{"issue":"1","key":"pone.0332574.ref020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40122-021-00343-z","article-title":"Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology","volume":"11","author":"N Dasgupta","year":"2022","journal-title":"Pain Ther"},{"issue":"2","key":"pone.0332574.ref021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.gerinurse.2021.01.005","article-title":"Drug modification by nurses in Norwegian nursing homes: A cross-sectional study","volume":"42","author":"H Solberg","year":"2021","journal-title":"Geriatr Nurs"},{"issue":"8","key":"pone.0332574.ref022","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1559-1816.2000.tb02462.x","article-title":"The Impact of Anonymity on Responses to Sensitive Questions1","volume":"30","author":"AD Ong","year":"2000","journal-title":"J Applied Social Pyschol"},{"issue":"3","key":"pone.0332574.ref023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1037\/a0028085","article-title":"Identifying careless responses in survey data","volume":"17","author":"AW Meade","year":"2012","journal-title":"Psychol Methods"},{"key":"pone.0332574.ref024","doi-asserted-by":"crossref","DOI":"10.1002\/9781394260645","volume-title":"Internet, Phone, Mail, and Mixed-Mode Surveys: The Tailored Design Method","author":"D Dillman","year":"2014","edition":"4"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:31:17Z","timestamp":1759944677000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332574"}},"subtitle":[],"editor":[{"given":"Hope","family":"Onohuean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332574","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}